Related Experiment Video
Updated: May 24, 2026

Demonstrating a Linear Relationship Between Vascular Endothelial Growth Factor and Luteinizing Hormone in Kidney Cortex Extracts
Published on: January 22, 2020
Fetuin-A serum levels are not correlated to kidney function in long-lived subjects
Chiara Bellia1, Rossella Tomaiuolo, Antonietta Caruso
1Sezione di Biochimica Clinica e Medicina Molecolare, Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Università degli Studi di Palermo, Italy.
Insights
Serum Fetuin A levels increase with age in elderly individuals. Lower levels of this protein were observed in those with specific AHSG gene variants, not linked to kidney function decline.
Area of Science:
- Biochemistry
- Gerontology
- Nephrology
Background:
- Serum Fetuin A inhibits ectopic calcification and is reduced in chronic kidney disease (CKD).
- Aging is associated with arterial stiffening and kidney function decline.
- Fetuin A is a potential link between CKD, arterial calcification, and aging.
Purpose of the Study:
- To investigate the association between serum Fetuin A levels and aging.
- To examine the relationship between serum Fetuin A and the AHSG T256S polymorphism.
- To explore the correlation of serum Fetuin A with kidney function in senescence.
Main Methods:
- Analysis of serum Fetuin A, Cystatin C, and AHSG T256S polymorphism in 256 elderly subjects (age 92 [81-100]).
- Serum Fetuin A measured by ELISA.
- AHSG T256S determined by PCR-RFLP.
Main Results:
- Serum Fetuin A significantly correlates with age (r=0.20, P=0.0048).
- AHSG TS and SS genotypes are associated with lower serum Fetuin A levels (P<0.027 and P<0.001, respectively).
- No significant correlation was found between Fetuin A and Cystatin C (kidney function marker).
Conclusions:
- Serum Fetuin A levels increase with age in elderly individuals.
- Individuals with TS or SS AHSG polymorphism exhibit lower circulating Fetuin A.
- The study did not find a correlation between serum Fetuin A and kidney function decline in aging individuals.
Objectives:
Serum Fetuin A has been identified as an inhibitor of ectopic calcification. It is reduced in subjects with chronic kidney disease (CKD) and it has been proposed as a potential link between CKD and the higher prevalence of arterial calcification observed in these patients. During aging both the stiffening of arterial wall due to calcification and a decline in kidney function are frequent. The aim of the study is to investigate if Fetuin A serum levels are associated with aging and with AHSG T256S polymorphism. Moreover, we aim at investigate whether serum Fetuin A is correlated to kidney function in this setting of senescence.
Design And Methods:
256 health long-lived subjects (age 92 [81-100]) were recruited for the study. Serum Fetuin A was evaluated by ELISA, Cystatin C by immune-nephelometry. AHSG T256S was determinated by PCR-RFLP.
Results:
Serum Fetuin A shows a significant correlation with age (r=0.20; P=0.0048). AHSG TS and SS genotypes are associated to lower levels of serum protein (0.27 [0.19-0.29] g/L vs 0.42 [0.32-0.49] g/L; P<0.027 and 0.34 [0.25-0.41] g/L vs 0.42 [0.32-0.49] g/L; P<0.001, respectively). No significant correlation between Fetuin A and Cystatin C was observed.
Conclusions:
Serum Fetuin A increases with age in elder individuals and subjects with the TS or SS AHSG polymorphism have lower levels of the circulating protein. No correlation with kidney function decline was observed. Other mechanisms should be investigated to explain the increase of Fetuin A with age.
Related Concept Videos
Serum Studies: Renal Function Tests
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

